79 results about "Colon carcinoma" patented technology

This invention relates to novel nucleic acid sequences which are differentially expressed in cancer cells. The invention also relates to proteins and peptides encoded by the sequences, to diagnostic assays and therapeutic agents based on the sequences and proteins, and to probes, antisense constructs, and antibodies derived from the sequences and proteins or peptides. The subject nucleic acids have been found to be differentially expressed by tumor cells, particularly in colon cancer tissue.

The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.

The invention relates to compositions comprising caveolin polypeptides and nucleic acids, and methods of use thereof. The invention is useful in the treatment of non-steroid dependent carcinoma, especially for treatment of gastrointestinal carcinoma. According to the invention, caveolin-1 or the gene encoding caveolin are especially preferred to treat colon carcinoma.

The invention discloses a method for identifying micro ribonucleic acid in the blood serum of colon carcinoma patients through a Solexa technique, belongs to the technical field of biological medicine, and particularly relates to the Solexa technique that researches on the micro ribonucleic acid expression in the blood serum and the application of the Solexa technique in colon carcinoma diagnosis. The method for identifying the micro ribonucleic acid in the blood serum of colon carcinoma patients comprises measuring an expression profiling of the micro ribonucleic acid in the blood serum of a colon carcinoma subject by applying the Solexa sequencing method. The Solexa sequencing method has the advantages of wide measuring pedigree, high sensitivity, convenient materials obtaining and easy sample storing, etc., and can be widely used for relevant tasks such as disease census measuring, which can improve low specificity and low sensitivity that are caused by individual difference and are difficult to be overcome by single markers, and remarkably improve the clinical relevance ratio of diseases, and is an effective method for disease diagnosis in early stages.

The invention belongs to the technical field of biological pharmacy, and concretely relates to a PD-L1 IgV affinity peptide S10 product with antitumor activity, and preparation and application thereof. The affinity peptide S10 is specifically bond at PD-l1 IgV region, has the amino acid sequence of WSHGGHQHFIRF, and has the molecular weight of 1507.7. The affinity peptide S10 is prepared through a Fomc solid-phase peptide synthesis method, and plays a role as a main active composition for preparing anti-colorectal carcinoma medicines. The provided affinity peptide S10 is obtained by utilizing a phage-display peptide-library screening technology and taking PD-L1 IgV as a target for performing high-flux screening. Experiments of bearing a cancer in a mouse prove that affinity peptide S10 has relatively good antitumor activity, is capable of obviously inhibiting growth of tumor in a mouse, and provides new thinking and theoretical base for research and exploitation of medicines based on PD-L1.

Monoclonal antibodies, in particular 33.28 and 31.1, and chimeric antibodies, in particular mouse / humans chimeric Chi #1 specific for glycoprotein antigens of colon carcinoma-associated antigens which are immunogenic in humans, are disclosed. Such antibodies, and fragments and derivatives thereof, are useful in immunodiagnosis and immunotherapy of human colon, breast, and ovarian cancer, and for purification of antigens which can serve as immunotherapeutic agents. Methods of detecting the colon carcinoma-associated antigen in a sample, and methods for treating subjects having colon, breast, and ovarian carcinomas are disclosed.

The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

The invention discloses a novel boric acid derivative and a medicinal composition thereof, and belongs to the field of pharmaceutical chemistry. The boric acid derivative is a compound represented byformula (I). The invention also provides uses of the boric acid derivative in the preparation of an antitumor medicine or a proteasome inhibitor medicine. The uses concretely comprise a use of the boric acid derivative in the preparation of proteasome and chymotrypsin protease inhibitors, and a use in the preparation of medicines for preventing and / or treating multiple myeloma, colorectal carcinoma and other cancers. The novel boric acid derivative provides a new choice for clinically screening and / or preparing proteasome inhibitor medicines and multiple myeloma and colorectal carcinoma medicines, and has a wide application prospect.

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

This invention relates to novel nucleic acid sequences which are differentially expressed in cancer cells. The invention also relates to proteins and peptides encoded by the sequences, to diagnostic assays and therapeutic agents based on the sequences and proteins, and to probes, antisense constructs, and antibodies derived from the sequences and proteins or peptides. The subject nucleic acids have been found to be differentially expressed by tumor cells, particularly in colon cancer tissue.

The present invention is based, in part, on the discovery that GOLPH3 plays a role in cancer, including lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma. Accordingly, the invention relates to compositions, kits, and methods for diagnosing, prognosing, and monitoring cancer, e.g., lung, ovarian, pancreatic, liver, breast, prostate, and colon carcinomas, as well as melanoma and multiple myeloma.

The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention. Also provided is a TADG-14 protein variant that has a potential role for detecting and targeting of ovarian carcinomas.

The invention discloses medical applications of four buxus alkaloids compounds in the preparation of antitumor medicines. Experiment results show that the four compounds KBA01, KBA02, KBA03 and KBR18, under the condition of concentration without toxicity to wild normal mouse embryonic fibroblast cells, can selectively kill mouse tumor cells with tumor specific mutant genes p53 and Ras; accordingly, the compounds are very strong in killing activity to human colon cancer cell strains with p53 mutants, but not strong in killing activity to human wild colon cancer cell strains with p53 mutants; and as shown in a GFP (Green Fluorescence Protein) reporter vector screening system of a gene promoter, the compounds KBA02 and KBA03 can activate a promoter of a cancer suppressor gene p16. The characteristics indicate that the compounds from the four buxus plant origins have application potentials for preparing personalized treatment medicines aiming at the tumor mutant genes p53 and Ras as well as the cancer suppressor gene p16.

Disclosed are novel compositions, methods and vaccines, which upon administration to a patient suffering from a melanoma, colon carcinoma tumor or breast cancer, postpone and / or reduce the need for chemotherapy treatment, slow the progression of or eliminate the tumor and / or alleviate the symptoms of the tumor. The compositions comprise stressed colon carcinoma, melanoma or breast cancer cells, preferably autologous such cells.

The invention provides a human colon carcinoma cell line DXH-1, which is derived from primary lesion of human sigmoid colon carcinoma, and application of the human colon carcinoma cell line as a human colon carcinoma occurrence, human colon carcinoma development or human colon carcinoma transfer cell model, application of the human colon carcinoma cell line in establishing a human colon carcinoma animal model and application of the human colon carcinoma cell line in researching a human colon carcinoma occurrence mechanism and / or medicines for treating the human colon carcinoma. The human colon carcinoma cell line DXH-1 disclosed by the invention can be stably transferred for more than 50 generations, so that an appropriate material is provided for colorectal carcinoma mechanism and drug screening. In an in-vivo nude mice experiment, the human colon carcinoma cell line shows a relatively strong tumorigenesis cavity, and the cell line, transplanted subcutaneously in nude mice by 1*106 cells, is capable of promoting 100% (5 / 5) tumorigenesis after 35 days; the DXH-1 cell has certain drug resistance to colon carcinoma chemotherapeutics (5FU, such as oxaliplatin, irinotecan and the like), so that a material is provided to the researches on a colon carcinoma chemotherapeutic resistance mechanism; and the human colon carcinoma cell line DXH-1 is preserved in China Center for Type Culture Collection in Wuhan University, Wuhan, China with number of CCTCC No: C201543.

Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

The invention relates to preparation and application of a novel organo-antimony complex (1). The complex (1) has the characteristics of high anticancer activity, large water solubility, small toxic side effect and the like. A drug effect composition containing the complex (1) is used for treating various solid cancers, such as lung cancer, gastric carcinoma, liver cancer, breast carcinoma, cancer of colon, ovarian cancer, cervical carcinoma, leukemia, lymphoma, nasopharyngeal darcinoma and the like.

The present invention provides methods for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence or absence of or determining the amount of one or more carcinoma associated markers. Further, the present invention provides methods for determining whether a tissue should be surgically resected and for determining the territorial extent of resection. The carcinoma markers may be those provided in FIG. 1. The present invention also provides a diagnostic kit for diagnosing carcinoma, providing a prognosis for a carcinoma or assessing the likelihood that a tissue may become cancerous by identifying the presence of or determining the amount of one or more carcinoma associated markers. The methods and kits are especially useful regarding colon, rectal or colorectal carcinoma.

The invention relates to the use of gene expression profiles for predicting the probability of recurrence or metastases to develop in remote organs of patients from which a primary colon carcinoma has been removed.

The invention provides a preparation method of compounds with the structure represented by general formula 1, and an application of the compounds in the preparation of antitumor drugs. The compounds are prepared through ester bond condensation of a 3th hydroxyl group of an anticancer lead compound TOA (patent 201110055102.X) and a carboxyl group of amino acids; and the compounds have a more substantial inhibition effect on liver cancer, colorectal carcinoma, cervical carcinoma and stomach cancer cell lines than the TOA, have smaller toxicity to normal cells than cis-platinum, have obviously better water solubility than the TOA, and are especially suitable for preparing antitumor treatment drugs.

The invention relates to compositions comprising caveolin polypeptides and nucleic acids, and methods of use thereof. The invention is useful in the treatment of non-steroid dependent carcinoma, especially for treatment of gastrointestinal carcinoma. According to the invention, caveolin-1 or the gene encoding caveolin are especially preferred to treat colon carcinoma.

The subject invention provides Coriolus versicolor extracts, pharmaceutical compositions comprising the Coriolus versicolor extracts, methods of preparation, and therapeutic uses thereof. Advantageously, the subject Coriolus versicolor extract has immunomodulatory, anti-tumor, anti-microbial, and antiviral effects. In a preferred embodiment, the subject invention can be used to inhibit the metastatic spread of cancer cells. In certain preferred embodiments, the subject invention can be used to treat glioblastoma multiforme, nasopharyngeal carcinoma, breast carcinoma, lung carcinoma, prostate cancer, and colon carcinoma, as well as bacterial, viral, fungal, protozoan, and / or other microbial infection.

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP / seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

The invention belongs to the fields of genetic engineering and medical detection, and relates to a human colorectal carcinoma molecular marker COL3A1 and an application thereof in preparing a human colorectal carcinoma detecting preparation or a detecting kit. On the basis of an experiment of analyzing the expression of a COL3A1 gene in colorectal carcinoma and para-carcinoma tissues, a result shows that the COL3A1 gene has a more significant high-expression trend in the carcinoma tissues in comparison with that in the para-carcinoma tissues, proving that the COL3A1 plays a role in the occurrence and development of the colorectal carcinoma; the COL3A1 presents significant different expression in colorectal carcinoma and para-carcinoma epithelial cells but has no expression difference in carcinoma and para-carcinoma matrix parts, showing that the COL3A1 protein is the carcinoma epithelial cell specificity molecular marker; and meanwhile, up-regulation of the expression of the COL3A1 gene is positively related to tumor progression and is related to the postoperative survival time of a patient with the colorectal carcinoma. The invention provides a scientific basis for the effective judgment of canceration progression of the human colorectal carcinoma.

The present invention provides a DNA encoding a novel extracellular serine protease termed Tumor Antigen Derived Gene-14 (TADG-14) which is overexpressed in ovarian, breast and colon carcinoma samples. Also provided are vector and host cells capable of expressing the DNA of the present invention, as well as the uses of the DNA and protein of the present invention.